title: [Modern antihyperglycaemic agents--what is the patient benefit?].
authors.affiliation: Städt. Klinikum München GmbH, Klinikum Bogenhausen, Klinik für Endokrinologie, Diabetologie und Angiologie, Englschalkinger Straße 77, D-81925, München, Deutschland. thorsten.siegmund@klinikum-muenchen.de.
authors.forename: Thorsten
authors.initials: T
authors.lastname: Siegmund
mesh_terms: D000284:Administration, Oral; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D018819:Dipeptidyl Peptidase 4 / Q000187:drug effects; D004359:Drug Therapy, Combination; D019983:Guideline Adherence; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives; D007333:Insulin Resistance; D008687:Metformin / Q000627:therapeutic use; D051269:Sodium-Glucose Transporter 1 / Q000037:antagonists & inhibitors; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; C495674:SLC5A1 protein, human; D051269:Sodium-Glucose Transporter 1; D008687:Metformin; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
keywords: DPP-4-inhibitors; SGLT2 inhibitors / GLP1- receptor agonist; Type 2 diabetes; antihyperglycemic medication